美股異動丨輝瑞盤前跌超2.6% 終止開發口服RSV療法
輝瑞(PFE.US)美股盤前跌超2.6%,報29.4美元。消息面上,輝瑞已終止兩項Sisunatovir治療呼吸道合胞病毒(RSV)感染的臨牀研究。Sisunatovir是一種口服RSV融合蛋白抑制劑,旨在阻止RSV病毒與宿主細胞的融合。輝瑞發言人表示:“Sisunatovir的臨牀開發面臨持續的挑戰,包括與抗酸藥的藥物相互作用。雖然輝瑞一直在努力解決這些挑戰,但最終決定終止Sisunatovir的開發,以集中精力發現和推進其他在研療法的開發,這些療法最有可能預防和治療RSV疾病和其他呼吸道病毒感染。”

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.